These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 18341379)

  • 41. Old and new: evidence-based evaluation of interventions for Graves' Orbitopathy.
    Ezra DG; Rose GE
    Br J Ophthalmol; 2014 Mar; 98(3):287-8. PubMed ID: 24311524
    [No Abstract]   [Full Text] [Related]  

  • 42. Presentation of Graves' orbitopathy within European Group On Graves' Orbitopathy (EUGOGO) centres from 2012 to 2019 (PREGO III).
    Schuh A; Ayvaz G; Baldeschi L; Baretić M; Bechtold D; Boschi A; Brix TH; Burlacu MC; Ciric J; Covelli D; Currò N; Donati S; Eckstein AK; Fichter N; Führer D; Horn M; Jabłońska-Pawlak A; Juri Mandić J; Kahaly GJ; Konuk O; Langbein A; Lanzolla G; Marcocci C; Marinò M; Miśkiewicz P; Beleslin BN; Pérez-Lázaro A; Pérez-López M; Ponto KA; Quinn A; Rudofsky G; Salvi M; Schittkowski MP; Tanda ML; Toruner F; Vaidya B; Hintschich CR
    Br J Ophthalmol; 2024 Jan; 108(2):294-300. PubMed ID: 36627174
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Graves' Orbitopathy].
    Eckstein A; Esser J; Mattheis S; Berchner-Pfannschmidt U
    Klin Monbl Augenheilkd; 2016 Dec; 233(12):1385-1407. PubMed ID: 27871109
    [No Abstract]   [Full Text] [Related]  

  • 44. Comment on the 2021 EUGOGO Clinical Practice Guidelines for the Medical Management of Graves' Orbitopathy.
    Smith TJ
    Eur J Endocrinol; 2021 Oct; 185(6):L13-L14. PubMed ID: 34619659
    [No Abstract]   [Full Text] [Related]  

  • 45. Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy.
    Laurberg P; Berman DC; Andersen S; Bülow Pedersen I
    Thyroid; 2011 Sep; 21(9):951-6. PubMed ID: 21834677
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [What's new in endocrinology].
    Mavromati M; Leboulleux S
    Rev Med Suisse; 2022 Jan; 18(764-5):26-30. PubMed ID: 35048575
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Management of Graves' orbitopathy in Latin America: an international questionnaire study compared with Europe.
    Ramos HE; Diehl LA; Camacho CP; Perros P; Graf H;
    Clin Endocrinol (Oxf); 2008 Dec; 69(6):951-6. PubMed ID: 18462263
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A symposium on thyroid-associated ophthalmopathy, also known as Graves' orbitopathy at the Jules Stein Eye Institute at the University of California, Los Angeles.
    Douglas RS; Goldberg RA; Smith TJ
    Thyroid; 2008 Sep; 18(9):931. PubMed ID: 18788916
    [No Abstract]   [Full Text] [Related]  

  • 49. Quality of life of patients with thyroid eye disease: 3-year follow-up in a multidisciplinary clinic in Israel.
    Zloto O; Sagiv O; Priel A; Cukierman-Yaffe T; Tirosh A; Agmon-Levin N; Madgar S; Serlin T; Ben Simon G
    Graefes Arch Clin Exp Ophthalmol; 2021 Jul; 259(7):2009-2015. PubMed ID: 33528651
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Editorial. Graves' orbitopathy.
    von Arx GF
    Orbit; 2009; 28(4):209-13. PubMed ID: 19839876
    [No Abstract]   [Full Text] [Related]  

  • 51. Prevention of graves' orbitopathy: early diagnosis of thyroid-associated orbitopathy in Graves' disease.
    Mourits MP
    Orbit; 2008; 27(6):399-400. PubMed ID: 19085291
    [No Abstract]   [Full Text] [Related]  

  • 52. Editorial: Mechanisms and Novel Therapies in Graves' Orbitopathy: Current Update.
    Zhou H; Muller I; Chong KK; Ludgate M; Fang S
    Front Endocrinol (Lausanne); 2022; 13():902591. PubMed ID: 35574000
    [No Abstract]   [Full Text] [Related]  

  • 53. Management of Graves' ophthalmopathy.
    Wiersinga WM
    Nat Clin Pract Endocrinol Metab; 2007 May; 3(5):396-404. PubMed ID: 17452966
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Orbital lymphoma associated with Graves' disease: A case report.
    Hajduković Z; Kuzmić-Janković S; Kljaković-Avramović T; Sekulović L; Tukić L
    Vojnosanit Pregl; 2014 May; 71(5):510-4. PubMed ID: 26137719
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Statin reduces orbitopathy risk in patients with Graves' disease by modulating apoptosis and autophagy activities.
    Bifulco M; Ciaglia E
    Endocrine; 2016 Sep; 53(3):649-50. PubMed ID: 26438397
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Short-tau inversion-recovery (STIR) sequence magnetic resonance imaging evaluation of orbital structures in Graves' orbitopathy].
    Rodríguez-González N; Pérez-Rico C; López-Para Giménez R; Arévalo-Serrano J; Del Amo García B; Calzada Domingo L; Flores Ruiz L; Blanco R
    Arch Soc Esp Oftalmol; 2011 Nov; 86(11):351-7. PubMed ID: 22040641
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Management plan and delivery of care in Graves' ophthalmopathy patients.
    Yang M; Perros P
    Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):303-11. PubMed ID: 22632367
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunotherapy for Graves' orbitopathy: easy enthusiasm, but let's keep trying.
    Bartalena L; Tanda ML
    J Endocrinol Invest; 2006 Dec; 29(11):1012-6. PubMed ID: 17259800
    [No Abstract]   [Full Text] [Related]  

  • 59. [Graves' orbitopathy].
    Eckstein A; Esser J
    Klin Monbl Augenheilkd; 2011 May; 228(5):432-8. PubMed ID: 21534176
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Understanding the pathogenesis of Graves' orbitopathy: A new age paradigm.
    Kurian DE; Kalra S; Kapoor N
    J Pak Med Assoc; 2022 Apr; 72(4):767-770. PubMed ID: 35614620
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.